Trazimera

TRAZIMERA is a biosimilar* to Herceptin® (trastuzumab) that was approved by the FDA based on the totality of evidence1,2
TRAZIMERA offers the potential to help address treatment costs and shows no clinically meaningful differences to
Herceptin1-3

Clinical Information

*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar and the reference product.
WAC is a manufacturer's undiscounted or list price to wholesalers/direct purchasers and, therefore, is not inclusive of discounts to payers, providers, distributors, and other purchasing organizations. Data as of February 2020.
Medical policy data are current as of February 2021. Please verify patient benefits to confirm coverage.
§NCCN Guidelines® recommend the use of an FDA-approved biosimilar as an appropriate substitute for trastuzumab. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
||Terms and Conditions
By using this program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions below:
  • The Pfizer Oncology Together Co-Pay Savings Program for Injectables for TRAZIMERA is not valid for patients who are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
  • Program offer is not valid for cash-paying patients.
  • With this program, eligible patients may pay as little as $0 co-pay per TRAZIMERA treatment, subject to a maximum benefit of $25,000 per calendar year for out-of-pocket expenses for TRAZIMERA including co-pays or coinsurances.
  • The amount of any benefit is the difference between your co-pay and $0.
  • After the maximum of $25,000 you will be responsible for the remaining monthly out-of-pocket costs.
  • Patient must have private insurance with coverage of TRAZIMERA.
  • This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plans or other private health or pharmacy benefit programs.
  • You must deduct the value of this assistance from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
  • You are responsible for reporting use of the program to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the program, as may be required.
  • You should not use the program if your insurer or health plan prohibits use of manufacturer co-pay assistance programs.
  • This program is not valid where prohibited by law.
  • This program cannot be combined with any other savings, free trial or similar offer for the specified prescription.
  • This program is not health insurance.
  • This program is good only in the U.S. and Puerto Rico.
  • This program is limited to 1 per person during this offering period and is not transferable.
  • No other purchase is necessary.
  • Data related to your redemption of the program assistance may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other assistance redemptions and will not identify you.
  • Pfizer reserves the right to rescind, revoke or amend this program without notice.
  • This program may not be available to patients in all states.
  • For more information about Pfizer, visit www.pfizer.com.
  • For more information about the Pfizer Oncology Together Co-Pay Savings Program for Injectables, call 1-877-744-5675, or write to
    Pfizer Oncology Together Co-Pay Savings Program for Injectables
    P.O. Box 220366
    Charlotte, NC 28222
  • Program terms will expire at the end of each calendar year. Before the calendar year ends, you will receive information and eligibility requirements for continued participation.
For patients to be eligible for the Injectables Co-Pay Program for TRAZIMERA, they must have commercial insurance that covers TRAZIMERA and they cannot be enrolled in a state or federally funded insurance program. Whether a co-pay expense is eligible for the Injectables Co-Pay Program for TRAZIMERA benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for TRAZIMERA administered in the outpatient setting.
#The Injectables Co-Pay Program for TRAZIMERA will pay the co-pay for TRAZIMERA up to the annual assistance limit of $25,000 per calendar year per patient.
**The Injectables Co-Pay Program for TRAZIMERA provides assistance for eligible, commercially insured patients prescribed TRAZIMERA for co-pays or coinsurance incurred for TRAZIMERA up to $25,000 per calendar year. It does not cover or provide support for supplies, services, procedures, or any other physician-related services associated with TRAZIMERA treatment.
 
References:
  1. TRAZIMERA [prescribing information]. New York, NY: Pfizer Inc.; November 2020.
  2. US Food and Drug Administration. Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Silver Spring, MD: FDA, US Dept of Health and Human Services; April 2015. https://www.fda.gov/downloads/drugs/guidances/ucm291128.pdf. Accessed February 22, 2021.
  3. Data on file. Pfizer Inc., New York, NY.
  4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.6.2020. © 2020 National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the guideline, go online to NCCN.org.
  5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Gastric Cancer V.2.2020. © 2020 National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the guideline, go online to NCCN.org.